van der Pluijm G, Mouthaan H, Baas C, de Groot H, Papapoulos S, Löwik C
University Hospital, Department of Endocrinology and Metabolic Diseases, Leiden, The Netherlands.
J Bone Miner Res. 1994 Jul;9(7):1021-8. doi: 10.1002/jbmr.5650090709.
We investigated possible inhibitory effects of five synthetic Arg-Gly-Asp (RGD)-containing peptides on osteoclastic resorption in three distinct in vitro resorption assays (17-day-old fetal mouse bone organ cultures) that differ in stages of osteoclast differentiation. RGD peptides, which can bind the adhesion receptors called integrins, inhibited osteoclastic resorption (45Ca release) in fetal mouse bone explants in which osteoclast precursors have yet to adhere to the mineralized matrix and develop into mature osteoclasts (metacarpals and coculture system). Treatment of metacarpals with RGD peptides inhibited the formation of multinucleated TRAP+ osteoclasts in the mineralized matrix because their mononuclear TRAP+ osteoclast precursors remained localized in the periosteum. In particular, echistatin, a viper venom protein with known affinity for alpha v beta 3 integrin, and GdRGDSP inhibited osteoclastic resorption dose dependently in these systems (ED50 10(-9) and 10(-4) M, respectively) but did not alter the activity of mature resorbing osteoclasts in radii. In addition, 45Ca release was significantly inhibited by the cyclic peptide GPenGRGDSPCA, which has a relatively higher affinity for the vitronectin than fibronectin receptor(s). In contrast, GRDGdSP, which has a much higher affinity for the fibronectin receptor (than the vitronectin receptors), had no effect on resorption at similar concentrations in any resorption system used. In summary, the data presented in this paper show that peptides with RGD motifs are capable of inhibiting osteoclastic resorption in bone organ cultures. Our studies not only support the hypothesis concerning the importance of alpha v beta 3 in osteoclastic resorption but also suggest an important role of integrin(s) in events preceding the actual resorption of calcified matrix by osteoclasts.
我们在三种不同的体外吸收试验(17日龄胎鼠骨器官培养)中研究了五种合成的含精氨酸-甘氨酸-天冬氨酸(RGD)肽对破骨细胞吸收的可能抑制作用,这三种试验在破骨细胞分化阶段有所不同。RGD肽能够结合称为整合素的黏附受体,在胎鼠骨外植体中抑制破骨细胞吸收(45Ca释放),在这些外植体中破骨细胞前体尚未附着于矿化基质并发育为成熟破骨细胞(掌骨和共培养系统)。用RGD肽处理掌骨可抑制矿化基质中多核TRAP+破骨细胞的形成,因为它们的单核TRAP+破骨细胞前体仍局限于骨膜。特别是,echistatin(一种对αvβ3整合素有已知亲和力的蝰蛇毒蛋白)和GdRGDSP在这些系统中剂量依赖性地抑制破骨细胞吸收(ED50分别为10(-9)和10(-4) M),但不改变桡骨中成熟吸收性破骨细胞的活性。此外,环状肽GPenGRGDSPCA对45Ca释放有显著抑制作用,该环状肽对玻连蛋白的亲和力相对高于纤连蛋白受体。相比之下,对纤连蛋白受体(比对玻连蛋白受体)亲和力高得多的GRDGdSP在任何所用的吸收系统中,在相似浓度下对吸收均无影响。总之,本文所呈现的数据表明,具有RGD基序的肽能够在骨器官培养中抑制破骨细胞吸收。我们的研究不仅支持了关于αvβ3在破骨细胞吸收中重要性的假说,还表明整合素在破骨细胞实际吸收钙化基质之前的事件中起重要作用。